Placebo-based studies have been called “groundbreaking” and “game-changing.”
It is imperative for anyone who suffers from a brain or memory disorder of any type, suspected or otherwise, to visit their doctor. Though I had worked as a mental health professional for several years, I no longer practice. Therefore, no medical advice will be offered herein on my part.
All listed theories and facts within this article are fully-attributed to several medical experts and scientists as listed within the following outlets: UpsidetoAging.com, TheConversation.com, and CNN.com.
I have written extensively on the related topics of Alzheimer’s and dementia for NewsBreak. My previous article on those matters, “A Dementia and Alzheimer’s Treatment is Gaining in Popularity,”excerpted the following from TheUpsidetoAging.com’s “Dementia Care: The Benefits of Staying in Their Reality”: Arguing with someone who has dementia is futile and will often exasperate the situation. Whether we think they are making up these stories or not when we attempt to correct them we are essentially calling them a liar and taking away any sense of control they may have in telling these stories. The Alzheimers Association also stresses the importance of communication with those living with dementia and Alzheimer’s and notes that communication requires patience, understanding, and good listening skills.
In recent days, however, a new drug has been widely reported upon that promises to physically slow down Alzheimer’s progression.
Let us explore further.
Alzheimer’s and Dementia Study, 2022
TheConversation.com reported on October 4th, in its article entitled “New Alzheimer’s Drug Slows Cognitive Decline – and May be Available as Early as Next Year,” the early promise of the pioneering treatment: Lecanemab is the first drug to help improve the symptoms of Alzheimer’s by slowing the disease. These are very promising results, although the only data we have at the moment is from the drugmaker’s press release. Lecanemab is an antibody that finds and removes a protein called amyloid that builds up and forms clumps in the brains of people with Alzheimer’s disease. By targeting amyloid, lecanemab is striking at the heart of the disease itself, rather than just treating symptoms by boosting brain chemicals in the cells that are still working (as is the case with drugs currently prescribed for Alzheimer’s).
The article further stated: Regardless of whether other biological processes are important in the development of Alzheimer’s, the data from the phase 3 lecanemab trial tells us that amyloid is a central problem in the disease. This will help focus future investment in clinical trials and laboratory research.
According to CNN.com’s October 4th piece, “After Promising Data, Experts Say Many Questions Remain Over an Experimental Alzheimer’s Drug,” the latest studies regarding the drug are optimistic, though more studies need to be completed: The experimental Alzheimer’s drug lecanemab made big news last week when the companies testing it released trial results that showed the drug met its goals, making it one of the first dementia drugs to return positive results. In a randomized, placebo-controlled study of nearly 1,800 people who were in the early stages of memory loss, those who were taking lecanemab had about 27% less decline after 18 months than those who did not, the companies said. The difference amounted to about half a point on a commonly used scale called the Clinical Dementia Rating – Sum of Boxes. The difference was statistically significant, indicating that the improvement probably wasn’t due to chance.
Further scrutiny of the experimental lecanemab is ongoing.
As I had mentioned in prior articles on the topic, many of us have or have had relatives or friends with dementia and/or Alzheimer’s. As such, empathy is of immense importance on this journey, for all involved parties.
I will share updates on this most recent study, here on NewsBreak, as they are reported.
Thank you for reading.